Last updated: May 29, 2026
BONSITY drug suppliers: who manufactures the active ingredient and finished dose products
BONSITY suppliers cannot be identified from the information provided. No active ingredient, dosage form, strength, regulatory status, label manufacturer, NDA/BLA number, or FDA product listing identifiers were included, and those identifiers are required to map the supply chain (API, drug product fill-finish, and packaging) to named vendors and contract manufacturers.
What companies supply the active pharmaceutical ingredient (API) for BONSITY?
Answer: Not determinable from the provided inputs.
Which API suppliers exist by API supplier role
- API manufacture (active ingredient)
- API purification and crystallization
- API secondary processing (polishing, milling)
- API supply agreement terms (long-term vs. spot procurement)
Where API supplier names typically appear
- FDA Drug Product Label (listed manufacturer/distributor)
- NDA/BLA application manufacturing section (Drug Substance)
- DMF holder and listed manufacturers (Drug Master File)
- cGMP inspection databases by facility address
- Import records tied to labeled importer of record
Which contract manufacturers make BONSITY drug product (tablets, capsules, injectables)?
Answer: Not determinable from the provided inputs.
Drug product manufacturing steps that drive supplier selection
- Finished dose blending and granulation (if solid oral)
- Tableting/encapsulation
- Sterile fill-finish (if injectable)
- Film coating and imprinting
- Packaging configuration (bottles vs unit dose, desiccant, cartons)
- Serialization and track-and-trace compliance
Where finished-dose suppliers are typically listed
- FDA label “Manufactured for” / “Distributed by” blocks
- Orange Book drug product listing and manufacturer fields
- Establishment registration (FDA eLIST by facility)
- Press releases on capacity and supply agreements
What is the Orange Book status of BONSITY and how does it identify manufacturers?
Answer: Not determinable from the provided inputs.
Orange Book fields that connect to suppliers
- Application number (NDA/BLA)
- Dosage form and strength
- Holder of application
- Listed drug product manufacturer(s)
- Patent numbers and exclusivity periods (useful for tracking product lineage)
Who are the ingredient and packaging vendors for BONSITY commercial supply?
Answer: Not determinable from the provided inputs.
Vendor categories commonly asked in supply-chain due diligence
- Excipients suppliers (cellulose, binders, lubricants, coatings)
- Specialty excipients (if used for solubility, taste masking, XR/ER platforms)
- Packaging suppliers (bottle, blister, cap, foil, cartons)
- QA release testing vendors (if outsourced)
- Cold-chain logistics partners (if temperature-controlled)
Which suppliers are best positioned for a generic or biosimilar supply entry for BONSITY?
Answer: Not determinable from the provided inputs.
What drives supplier readiness
- API accessibility (single-source vs multi-source)
- Compatibility of manufacturing scale with target label
- Ability to replicate formulation performance (dissolution, stability)
- Analytical method transfer readiness (assay, impurities, polymorph)
- Regulatory filing access (DMF/CEP/CTD module ownership)
How does BONSITY’s manufacturing network compare with other drugs in the same class?
Answer: Not determinable from the provided inputs.
Comparison dimensions used in sourcing strategy
- Number of approved drug product facilities
- Presence of in-house manufacturing vs contract manufacture
- DMF ownership concentration (high concentration increases continuity risk)
- Track record of FDA inspection outcomes for key facilities
Key Takeaways
- Named suppliers for BONSITY (API and finished dose contract manufacturers) cannot be identified because the necessary identifiers and product specifics are not provided.
- Supply-chain mapping for pharmaceuticals requires at minimum: active ingredient, dosage form/strength, labeled manufacturer and NDA/BLA identifier, or FDA listing identifiers.
- With those identifiers, supplier discovery typically proceeds through Orange Book and FDA label manufacturing blocks, DMFs, and facility registrations.
FAQs
- How do I identify the API supplier for an FDA-listed branded drug like BONSITY?
- Where do finished-dose contract manufacturers show up in FDA submissions for branded drugs?
- What does Orange Book listing reveal about manufacturing and supply risk?
- How do DMFs and site registrations connect to specific API manufacturers?
- What information sources are used to confirm bottling, blistering, and packaging suppliers for prescription drugs?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA database).
- U.S. Food and Drug Administration. Drugs@FDA. (FDA database).
- U.S. Food and Drug Administration. Drug Establishment Registration and Listing System (eLIST). (FDA database).
